Which company develops and produces Brigatinib?

Brigatinib/Brigatinib (Brigatinib) is developed by the American biotechnology company Ariad Pharmaceuticals (Abbott Pharmaceuticals). Brigatinib/Brigatinib is a targeted drug used to treat non-small cell lung cancer (NSCLC). It belongs to the tyrosine kinase inhibitor (TKI) class of drugs. Its mechanism of action is to inhibit specific tyrosine kinases on tumor cells, thereby blocking cell signaling and inhibiting the growth and spread of tumors.

Brigatinib/Brigatinib is mainly used to treat ALK (ALK) rearranged NSCLC, which is a subtype of lung cancer caused by specific gene mutations. ALKfusion protein is an abnormal protein produced by the fusion of ALK gene and other genes. It is overexpressed in some NSCLC patients and promotes the development of tumors. Brigatinib/Brigatinib can selectively inhibit the activity of ALK fusion protein, thereby inhibiting the proliferation and survival of tumor cells.

In clinical trials, brigatinib/Brigatinib has shown significant efficacy in the treatment of ALK rearranged NSCLC patients. It can prolong progression-free survival and overall survival, and shows good tolerability and safety in both first- and second-line treatments.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. ForeignBrigatinib/BrigatinibThey are mainly generic drugs, mainly from Bangladesh and Laos. The price of the international version of the Bangladeshi generic drug Yaobin is about 2000 yuan, and the specification is 90mg*30 tablets; the price of the Lao version of the generic drug is about 600 and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.

xa0